

Management Program (FedRAMP) within GSA is responsible for providing a standardized, reusable approach to security assessment and authorization for cloud computing products and services that process unclassified information used by agencies.

Due to circumstances beyond the control of the DFO, the **Federal Register** notice for this meeting is being published fewer than 15 calendar days prior to the meeting due to unforeseen administrative difficulties.

The FSCAC will provide advice and recommendations to the Administrator of GSA, the FedRAMP Board, and agencies on technical, financial, programmatic, and operational matters regarding the secure adoption of cloud computing products and services. The FSCAC will ensure effective and ongoing coordination of agency adoption, use, authorization, monitoring, acquisition, and security of cloud computing products and services to enable agency mission and administrative priorities. The purposes of the Committee are:

- To examine the operations of FedRAMP and determine ways that authorization processes can continuously be improved, including the following:
 - Measures to increase agency reuse of FedRAMP authorizations.
 - Proposed actions that can be adopted to reduce the burden, confusion, and cost associated with FedRAMP authorizations for cloud service providers.
 - Measures to increase the number of FedRAMP authorizations for cloud computing products and services offered by small businesses concerns (as defined by section 3(a) of the Small Business Act (15 U.S.C. 632(a)).
 - Proposed actions that can be adopted to reduce the burden and cost of FedRAMP authorizations for agencies.
- Collect information and feedback on agency compliance with, and implementation of, FedRAMP requirements.

- Serve as a forum that facilitates communication and collaboration among the FedRAMP stakeholder community.

The FSCAC will meet no fewer than three (3) times a calendar year. Meetings shall occur as frequently as needed, called, and approved by the DFO.

Purpose of the Meeting and Agenda

The November 16, 2023 public meeting will be dedicated to the Committee members' feedback and discussion on OMB's draft memo titled "Modernizing the Federal Risk

Authorization Management Program (FedRAMP)." The Committee will then finalize and vote on their deliverable to the GSA Administrator regarding their recommendations on the OMB memo. The meeting agenda and draft OMB memo will be posted on <https://gsa.gov/fscac> prior to the November 16, 2023 meeting.

Meeting Attendance

This virtual meeting is open to the public. Meeting registration and information is available at <https://gsa.gov/fscac>. Registration for attending the virtual meeting is highly encouraged by 5 p.m. EST, on Monday, November 13, 2023. After registration, individuals will receive instructions on how to attend the meeting via email.

For information on services for individuals with disabilities, or to request accommodation for a disability, please email the FSCAC staff at FSCAC@gsa.gov at least 10 days prior to the meeting date. Live captioning may be provided virtually.

Public Comment

Members of the public will have the opportunity to provide oral public comment during the FSCAC meeting by indicating their preference when registering. Written public comments can be submitted at any time by completing the public comment form on our website, <https://gsa.gov/fscac>. All written public comments will be provided to FSCAC members in advance of the meeting if received by Wednesday, November 8, 2023.

Elizabeth Blake,

Senior Advisor, Federal Acquisition Service, General Services Administration.

[FR Doc. 2023-24431 Filed 11-3-23; 8:45 am]

BILLING CODE 6820-34-P

GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090-0250; Docket No. 2023-0001; Sequence No. 6]

Information Collection; General Services Administration Acquisition Regulation; Federal Supply Schedule Contract Administration Information

AGENCY: Office of Acquisition Policy, General Services Administration (GSA).

ACTION: Notice of request for comments regarding an extension to an existing OMB information collection.

SUMMARY: Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division will be submitting to the Office of Management and Budget a request to review and

approve an extension of a previously approved information collection regarding Federal Supply Schedule contract administration information.

DATES: Submit comments on or before: January 5, 2024.

ADDRESSES: Submit comments identified by Information Collection 3090-0250, Federal Supply Schedule (FSS) Contract Administration Information via <http://www.regulations.gov>. Submit comments via the Federal eRulemaking portal by searching the OMB control number 3090-0250. Select the link "Comment Now" that corresponds with "Information Collection 3090-0250, FSS Contract Administration Information". Follow the instructions provided on the screen. Please include your name, company name (if any), and "Information Collection 3090-0250, FSS Contract Administration Information" on your attached document.

Instructions: Please submit comments only and cite Information Collection 3090-0250, FSS Contract Administration Information, in all correspondence related to this collection. Comments received generally will be posted without change to [regulations.gov](https://www.regulations.gov), including any personal and/or business confidential information provided. To confirm receipt of your comment(s), please check [regulations.gov](https://www.regulations.gov), approximately two-to-three days after submission to verify posting.

FOR FURTHER INFORMATION CONTACT: Ms. Vernita Misidor, Procurement Analyst, at GSARpolicy@gsa.gov or 202-357-9681.

SUPPLEMENTARY INFORMATION:

A. Purpose

GSA requires information from Federal Supply Schedule contractors that will be used to conduct award oversight or generate mandatory reports during contract administration. For these contractors, providing commercial supplies and services, much of this information is readily available to the public at large, or is routinely exchanged by firms during the normal course of business. This general information collection covers these contract administration requirements, as outlined in GSAR Subpart 538.2—Establishing and Administering Federal Supply Schedules.

B. Annual Reporting Burden

This information collection requires no expenditure of resources to gather the information for submission, as the information is often exchanged by commercial business firms in their

catalogs or other public documents during the normal course of business. The nominal amount of burden imposed on the public is simply to relay the requested information.

Respondents: 14,000.

Responses per Respondent: 1.

Total Annual Responses: 14,000.

Hours per Response: 0.03 (2 minutes).

Total Burden Hours: 420.

C. Public Comments

Public comments are particularly invited on: Whether this collection of information is necessary and whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate and based on valid assumptions and methodology; and ways to enhance the quality, utility, and clarity of the information to be collected.

Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the Regulatory Secretariat Division, at GSARegSec@gsa.gov.

Please cite OMB Control No. 3090–0250, FSS Contract Administration Information, in all correspondence.

Jeffrey A. Koses,

Senior Procurement Executive, Office of Acquisition Policy, Office of Government-wide Policy.

[FR Doc. 2023–24433 Filed 11–3–23; 8:45 am]

BILLING CODE 6820–14–P

GENERAL SERVICES ADMINISTRATION

[Notice-MRB–2023–06; Docket No. 2023–0002; Sequence No. 37]

GSA Acquisition Policy Federal Advisory Committee; Notification of Upcoming Web-Based Public Meeting

AGENCY: Office of Government-wide Policy (OGP), General Services Administration (GSA).

ACTION: Meeting notice.

SUMMARY: GSA is providing notice of a meeting of the GSA Acquisition Policy Federal Advisory Committee (hereinafter “the Committee” or “the GAP FAC”) in accordance with the requirements of the Federal Advisory Committee Act (FACA). This meeting will be open to the public, accessible via webcast. Information on attending and providing written public comment is under the **SUPPLEMENTARY INFORMATION** section.

DATES: The GAP FAC will hold an open public meeting on Tuesday, December 5, 2023, from 1 p.m. to 4:30 p.m. eastern standard time (EST).

ADDRESSES: The meeting will be accessible via webcast. Registrants will receive the webcast information before the meeting.

FOR FURTHER INFORMATION CONTACT:

Boris Arratia, Designated Federal Officer, OGP, 703–795–0816, or email: boris.arratia@gsa.gov; or Stephanie Hardison, OGP, 202–258–6823, or email: stephanie.hardison@gsa.gov. Additional information about the Committee, including meeting materials and agendas, are available on-line at <https://gsa.gov/policy-regulations/policy/acquisition-policy/gsa-acquisition-policy-federal-advisory-committee>.

SUPPLEMENTARY INFORMATION:

Purpose of the Meeting

The purpose of this meeting is for each of the three subcommittees (Policy and Practice, Industry Partnerships, and Acquisition Workforce) to present recommendations to the full Committee. The Committee will, in turn, deliberate and vote on GAP FAC recommendations to be delivered to the GSA Administrator.

Meeting Agenda

- Opening Remarks
- Guest Speaker
- Acquisition Workforce Subcommittee Recommendations and Discussion
- Vote on recommendations
- Industry Partnerships Subcommittee Recommendations and Discussion
- Vote on recommendations
- Policy and Practices Subcommittee Recommendations and Discussion
- Vote on recommendations
- Closing Remarks and Adjourn

Meeting Registration

This meeting is open to the public and will be accessible by webcast. Registration information is located on the GAP FAC website: <https://www.gsa.gov/policy-regulations/policy/acquisition-policy/gsa-acquisition-policy-federal-advisory-committee>. Public attendees who want to attend virtually will need to register no later than 5 p.m. EST, on Monday, December 4, 2023 to obtain the meeting webcast information. All registrants will be asked to provide their name, affiliation, and email address. After registration, individuals will receive webcast access information details via email.

Public Comments:

Written public comments are being accepted via email at gapfac@gsa.gov. To submit a written public comment, please email at gapfac.gsa.gov and

include your name, organization name (if applicable).

Jeffrey A. Koses,

Senior Procurement Executive, Office of Acquisition Policy, Office of Government-wide Policy.

[FR Doc. 2023–24432 Filed 11–3–23; 8:45 am]

BILLING CODE 6820–RV–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2023–P–2536]

Determination That FORADIL (Formoterol Fumarate) Inhalation Powder, 0.012 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) has determined that FORADIL (formoterol fumarate) inhalation powder, 0.012 milligrams (mg)/inhalation (inh), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for formoterol fumarate inhalation powder, 0.012 mg/inh, if all other legal and regulatory requirements are met.

FOR FURTHER INFORMATION CONTACT: Joe Thomas, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6217, Silver Spring, MD 20993–0002, 202–815–5571, joseph.thomas1@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of an ANDA to market a generic version of a previously approved drug product. To obtain approval, the ANDA applicant must show, among other things, that the generic drug product: (1) has the same active ingredient(s), dosage form, route of administration, strength, conditions of use, and (with certain exceptions) labeling as the listed drug, which is a version of the drug that was previously approved; and (2) is bioequivalent to the listed drug. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

Section 505(j)(7) of the FD&C Act requires FDA to publish a list of all